Rocket Pharmaceuticals, Inc.
RCKT
$3.47
$0.133.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 358.89% | -11.89% | 15.49% | 26.97% | -12.37% |
| Total Depreciation and Amortization | -2.00% | -3.20% | -31.57% | 25.63% | -13.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,393.78% | 41.37% | -35.22% | -5.61% | 4.71% |
| Change in Net Operating Assets | 187.40% | -3,904.62% | 101.70% | -231.58% | 253.15% |
| Cash from Operations | 12.74% | -30.29% | 30.90% | -2.97% | 12.24% |
| Capital Expenditure | 91.40% | -16.25% | -248.15% | 208.00% | 86.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,122.10% | -51.95% | -60.98% | 194.12% | 155.16% |
| Cash from Investing | 1,128.56% | -52.10% | -61.09% | 194.75% | 154.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | 15,100.00% | -- | 100.00% | -131.16% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 725.82% | -1,863.22% | -96.32% | 353.88% | 85.08% |